-
Amgen's DMab scores in trials
For the biotech, a new drug for bone cancer and osteoporosis could mean a big boost in revenue.By Alyssa AbkowitzAn Amgen trial drug -- called denosum...
-
安進新藥DMab在試驗中獲得成功
對于安進這家生物技術公司而言，一種治療骨癌和骨質疏松癥的新藥可能使其收入大大增加。作者：Alyssa Abkowitz安進（Amgen）的一種試用藥物——名為狄諾塞麥(denosumab)——于7月7日達到新的里程碑，這家生物技術公司宣布了該藥物針對骨癌的最新臨床試驗結果。對2000多名患者的試驗顯...
-
Eli Lilly's patent problem
In 2009, Eli Lilly CEO John Lechleiter introduced a new drug development strategy called the Development Center of Excellence. The center's mission is...
-
Cisco's 'earth-shattering' announcement
For all you folks who had dreams of flying cars or Cisco (CSCO) announcing the purchase of EMC, what CEO John Chambers revealed Tuesday after weeks of...
-
Tim Geithner's latest headache
The treasury secretary's bid to rein in derivatives meets skepticism.By Carol J. LoomisThe Obama Administration has given itself two months to tell Co...
-
It's a phone! It's a browser! It's a wallet?
By Jessica ShamboraWill your cellphone soon become a proxy for your credit card? Zong and others are betting on it.If there’s one thing online merchan...
-
What's so great about working at Goldman?
The past 12 months have undoubtedly had Goldman Sachs (GS, Fortune 500) wishing for an invisibility cloak. The bank was sued by the SEC for trading ac...
-
科技業下一波浪潮：當大數據遇上生物學
去年12月，CVS提出以690億美元收購安進保險公司。今年1月，又有三大巨頭——亞馬遜、摩根大通和伯克謝爾哈撒韋表示要成立合資公司，降低共100萬左右員工的醫療成本并提高效果。之后3月，信諾保險表示將出資超過500億美元收購醫藥福利管理機構Express Scripts。為何近來醫療領域交易如此熱鬧...
-
Amazon's newest Kindle takes aim at newspapers
Amazon hopes to convert readers of magazines and newspapers to its newest e-book reader, the Kindle DX.By Jessica ShamboraThe question of whether Amaz...
-
制藥巨頭抱團能圓發財夢嗎？
三年前，美國衛生部門官員曾建議大型制藥公司共同開發治療藥物而不是相互競爭，當時這些公司的反應很矛盾。畢竟，大型制藥公司是競爭最激烈而且自我保護力度極大的領域之一。這些企業為本公司藥品的方方面面都申請了專利；對于侵害自己利益的對手，它們會予以回擊；專利到期后，為了阻擋競爭者，它們會發起價格戰。但現在，...
時間：
作者：
關鍵詞：
